Omnicell, Inc. (NASDAQ:OMCL - Get Free Report) hit a new 52-week high on Wednesday . The company traded as high as $52.51 and last traded at $52.04, with a volume of 183675 shares changing hands. The stock had previously closed at $40.12.
Analysts Set New Price Targets
A number of analysts recently weighed in on the company. Benchmark restated a "buy" rating and issued a $48.00 target price on shares of Omnicell in a research report on Wednesday, October 9th. JPMorgan Chase & Co. upped their price objective on shares of Omnicell from $26.00 to $37.00 and gave the company a "neutral" rating in a research note on Friday, August 23rd. Bank of America increased their target price on shares of Omnicell from $34.00 to $44.00 and gave the company a "buy" rating in a report on Friday, August 2nd. Wells Fargo & Company boosted their price target on shares of Omnicell from $30.00 to $41.00 and gave the stock an "equal weight" rating in a research note on Monday, October 14th. Finally, Barclays raised Omnicell from an "underweight" rating to an "equal weight" rating and raised their price objective for the company from $26.00 to $39.00 in a research note on Friday, August 2nd. Four investment analysts have rated the stock with a hold rating and four have given a buy rating to the company. According to data from MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and an average price target of $41.33.
Read Our Latest Stock Analysis on OMCL
Omnicell Price Performance
The company has a market cap of $2.44 billion, a PE ratio of -113.13, a P/E/G ratio of 43.55 and a beta of 0.83. The firm has a 50 day moving average of $42.95 and a two-hundred day moving average of $34.95. The company has a current ratio of 2.45, a quick ratio of 2.22 and a debt-to-equity ratio of 0.47.
Omnicell (NASDAQ:OMCL - Get Free Report) last posted its quarterly earnings data on Thursday, August 1st. The company reported $0.51 EPS for the quarter, beating analysts' consensus estimates of $0.14 by $0.37. The company had revenue of $276.80 million during the quarter, compared to analysts' expectations of $254.41 million. Omnicell had a positive return on equity of 2.52% and a negative net margin of 1.92%. Omnicell's revenue for the quarter was down 7.4% compared to the same quarter last year. During the same quarter in the prior year, the business earned $0.29 earnings per share. Research analysts predict that Omnicell, Inc. will post 0.64 earnings per share for the current fiscal year.
Hedge Funds Weigh In On Omnicell
Large investors have recently made changes to their positions in the company. Nisa Investment Advisors LLC grew its position in shares of Omnicell by 248.8% during the 2nd quarter. Nisa Investment Advisors LLC now owns 1,402 shares of the company's stock worth $38,000 after buying an additional 1,000 shares in the last quarter. GAMMA Investing LLC increased its position in shares of Omnicell by 78.4% in the 3rd quarter. GAMMA Investing LLC now owns 1,258 shares of the company's stock valued at $55,000 after acquiring an additional 553 shares during the period. EntryPoint Capital LLC increased its holdings in shares of Omnicell by 121.2% in the first quarter. EntryPoint Capital LLC now owns 2,455 shares of the company's stock valued at $72,000 after purchasing an additional 1,345 shares during the period. CWM LLC raised its position in Omnicell by 68.2% during the 2nd quarter. CWM LLC now owns 3,048 shares of the company's stock worth $83,000 after buying an additional 1,236 shares during the last quarter. Finally, 1620 Investment Advisors Inc. boosted its holdings in Omnicell by 230.1% in the third quarter. 1620 Investment Advisors Inc. now owns 2,212 shares of the company's stock valued at $96,000 after purchasing an additional 1,542 shares during the last quarter. 97.70% of the stock is owned by hedge funds and other institutional investors.
About Omnicell
(
Get Free Report)
Omnicell, Inc, together with its subsidiaries, provides medication management solutions and adherence tools for healthcare systems and pharmacies the United States and internationally. The company offers point of care automation solutions to improve clinician workflows in patient care areas of the healthcare system; XT Series automated dispensing systems for medications and supplies used in nursing units and other clinical areas of the hospital, as well as specialized automated dispensing systems for operating room; and robotic dispensing systems for handling the stocking and retrieval of boxed medications.
Featured Articles
Before you consider Omnicell, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Omnicell wasn't on the list.
While Omnicell currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Looking to avoid the hassle of mudslinging, volatility, and uncertainty? You'd need to be out of the market, which isn’t viable. So where should investors put their money? Find out with this report.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
